| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5c8af15af4401660858bbe5fba3091d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-60 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2016-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d55b538a16d090edad87e91907199b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dc46c9dfbff2e6ceb16e84ddba81a18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_920ddabaf2fd4d680783df83754d12ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e80ba64254c025333510401d9d4815a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b67ebc490e8c31f12e0e2190d5ef0cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3378d29a1b2ad605469c19073166f6a |
| publicationDate |
2018-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180029238-A |
| titleOfInvention |
A novel protein specific for LAG-3 |
| abstract |
The present application provides human tear lipocalin mutein that specifically binds to LAG-3. Such proteins can be used in many pharmaceutical applications such as, for example, anticancer agents and / or immunomodulators for the treatment or prevention of human diseases such as cancer, infectious diseases, autoimmune diseases and the like. The present invention also shows that human lipocalin mutein can inhibit the binding of LAG-3 to MHC class II in cells overexpressing MHC class II. The present invention also relates to a method for producing the LAG-3-binding lipocalin mutein described herein and to a composition comprising said lipocalin mutein. The present invention also relates to nucleic acid molecules encoding such lipocalin muteins and methods of producing such lipocalin muteins and nucleic acid molecules. In addition, the present application discloses compositions comprising one or more of these lipocalin muteins, as well as therapeutic and / or diagnostic uses of such lipocalin muteins. |
| priorityDate |
2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |